RU2360686C1 - Medicinal agent for oncotherapy - Google Patents

Abstract

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and can be used for therapy of tumours. Substance of the invention consists in application of 3,3'-diethylthiatricarbocyanine iodide C₂₅H₂₅N₂S₂·I of structural formula:

as an agent used in oncotherapy at single dosage 0.1 mg to 5 g taken up to 3 times a day.

EFFECT: invention allows improving therapeutic effectiveness ensured by recovered polarisation of molecules in introduction of low-toxic 3,3'-diethylthiatricarbocyanine iodide without by-effects.

9 cl, 13 ex

Description

The invention relates to new biologically active substances and can be used in medicine and biology as the basis for the creation of drugs. Currently, several dozens of anticancer pharmacological drugs are used in clinical oncology, the effectiveness of most of which is insufficient, and the spectrum of oncological diseases treated with chemotherapy is significantly limited. Researchers all over the world note the phenomenon of chemoresistance of cancer cells, even in patients who have never received chemotherapy. These facts speak of a crisis of the scientific and practical paradigm adopted in modern oncology. Therefore, the search for new drugs and treatment methods based on new mechanisms to suppress the growth of tumor cells, restore the tissues surrounding the tumor and metastases, is one of the most important tasks of oncology and pharmacology. One of the widely used anticancer drugs in clinical oncology is 5-fluorouracil, which is used to treat ovarian cancer, breast cancer, liver cancer (hapatoma), melanoma, etc. (Safit JN, Bonavida B. // Cancer Res. - 1992. - Vol. 52. - P.6630). Like all cytostatics, 5-fluorouracil is very toxic - with its use, nausea, vomiting, inhibition of bone marrow hematopoiesis, toxic damage to the kidneys, etc. (Mashkovsky MD Medicines. M., 2001, p. 425).

The drug “Fluorouracil”, which is a white or slightly yellowish, slightly soluble crystalline powder in water and in alcohol, is an antimetabolite, the antitumor activity of which is determined by its transformation in cancer cells into a competitive inhibitor involved in the synthesis of nucleic acids of the enzyme. This drug by intravenous injection is used for inoperable and recurrent cancer of the stomach, cancer of the colon and rectum, breast, ovaries, and pancreas, however, the drug has high toxicity and when it is used, inhibition of hematopoiesis, diarrhea, loss of appetite, vomiting, ulcerative stomatitis. In addition, this drug is contraindicated in the general serious condition of the patient, stomach ulcer and duodenal ulcer, severe functional liver failure (see, for example, Mashkovsky MD "Medicines", M., LLC "New Wave", Publisher SB. Divov, 2002, v. 2, p. 425).

The closest prototype is a drug consisting of tri-n-aminotriphenylchloromethane or a mixture thereof with dextrin (see RF patent No. 2252500 of 05/12/2004). However, this drug has a short duration of action, is ineffective in treating a number of tumors and is relatively toxic. The present invention relates to medicine, namely to medicines used to treat cancer.

The objective of the invention is the creation of funds with high antitumor activity and therapeutic effect in relation to various oncological diseases.

The technical result, which provides a solution to the problem, consists in using, as a means for treating cancer, a widely available and inexpensive substance, non-toxic, not causing side effects when used in pharmaceutically acceptable doses, reducing treatment time, increasing the effectiveness of treatment. Such substances include a heterocyclic compound, a chemical substance containing 3,3'-Diethylthiatricarbocyanine iodide. This drug is used in laser technology, purchased in Sigma. The therapeutic effect was achieved with the use of 3,3'-Diethylthiatricarbocyanine iodide in various pharmacological forms (solutions, suppositories, powders, etc.), the structural formula of this compound is as follows:

3,3'-Diethylthiatricarbocyanine iodide in the international classification: 3,3-diethilthiatricarbocyanine iodide C ₂₅ H ₂₅ N ₂ S ₂ .I

According to the criterion of acute toxicity, 3,3'-Diethylthiatricarbocyanine iodide refers to a medium toxic compound.

The therapeutic mechanism of action of this drug is based on its structural features. Its “long” molecule has high polarization properties and a number of features with respect to coherent light. It is very sensitive to light and has an extremely low threshold of excitation. According to the theory of M.V. Kutushov, malignancy is based on a violation of the polarization of molecules in cancer homeostasis and, as a result, isotropization of tissues and a distortion of the folding (folding) of proteins. In animal tissues, there is an initial extremely short stage of photosynthesis, dark and light respiration, fluorescence and luminescence, which are also perverted in cancerous tissues (MV Kutushov, “Dissymmetry of Life - Symmetry of Cancer.” Published by V. Secachev, p. 97, 2006). With the introduction of 3,3'-Diethylthiatricarbocyanine iodide, the polarization of the molecules, anisotropy are restored, which leads to the suppression of dark and light respiration, photosynthesis, the restoration of metabolism, the normalization of mitosis and the re-involution of cancer cells to normal.

The essence of the invention consists in the use of 3,3'-Diethylthiatricarbocyanine iodide C ₂₅ H ₂₅ N ₂ S ₂ .I (3,3-diethilthiatricarbocyanine iodide) having the structural formula:

as a means for the treatment of cancer with a single dose from 0.1 mg to 5 g per reception up to 3 times a day.

In special cases of application (implementation), 3,3'-Diethyltriatricarbocyanine iodide is used in dilution from 10 ^-7 to 10 ^-5 mmol / l in water or in physiological saline, 3,3'-Diethyltriatricarbocyanine iodide is taken before or after as an aqueous solution food, an aqueous solution of 3,3'-Diethylthiatricarbocyanine iodide is administered rectally, 1% solution of 3,3'-Diethylthiatricarbocyanine iodide is administered intravenously and intraperitoneally, 1% solution of 3,3'-Diethylthiatricarbocyanine iodide is administered inhalation, 1-5% ointment is used 3'-Diethylthiatricarbocyanine iodide, 3,3'-Diethylthiatricarbocyanine N iodide administered rectally in the form suppositories of 1-2%, 3,3'-Dietiltiatrikarbotsianin iodide solution was injected intramuscularly with a single dose of 100 to 200 mg.

Dosage forms were obtained by methods traditional for the pharmacy using conventional carriers, solvents, and other auxiliary ingredients (I.A. Muravyov, “Drug Technology”, M., 1980, “Pharmacist's Reference” / Edited by A.I. Tenzova, M., 1981).

The results of the study of the mechanism of action of the proposed drug are given in examples No. 1-4, and the possibility of its use for treatment is confirmed by examples No. 5-13.

Example No. 1.

In the test tubes of the experimental group with cancer cells A3 75 (metastatic human melanoma) in a buffer solution (10 ml), the drug was introduced in a dilution of 10 ^-6 mmol / L in the form of a solution of 3,3'-Diethylthiatricarbocyanine iodide.

In addition, Doxorubicin 10 ^-5 mmol / L in a buffer solution was introduced into tubes with the same pool of cancer cells in the same dilution, respectively.

At the same time, a control group was also formed from the same number of tubes and with the same components, except for cancer cells, instead of which fibroblasts were placed in the tubes of this group.

After temperature control for 3 days at a temperature of 37 ° C, the analysis of the contents of the above tubes was carried out.

A review of the results showed

In test tubes of the test group with the drug, the mitochondrial membranes are almost completely destroyed, and the picture is approximately the same for all variants of the drug used, in the test tubes of this group with the Doxorubicin preparation, membranes swell with partial (about 50%) destruction of the membranes, in cells located in a test tube with saline, no changes were detected.

In test tubes of the control group, mitochondrial membranes are swollen, but their integrity is preserved.

The data obtained indicate that the proposed drug causes a rearrangement of the mitochondrial membranes of cancer cells, but does not change the organelles and structures of normal cells.

Example No. 2.

In the test tubes of the experimental group with H69AR cancer cells (chemoresistant lung adenocarcinoma cells) in a buffer solution (10 ml), the drug 3,3'-Diethylthiatricarbocyanine iodide (No. 15) was introduced in a dilution from 10-3 to 10-7 mmol / l.

The control group - in tubes with the same pool of cancer cells, respectively, were introduced into one physiological solution, and in the other, Doxorubicin preparations.

Control group — Doxorubicin, which is presented on the graph as PC (Positive Control), was introduced into test tubes with the same pool of cancer cells. Thermostating for 72 hours at a temperature of 37 ° C, after which the analysis of proliferative activity.

Consideration of the results in examples 1 and 2 showed

In test tubes of the test group with the drug administered, the suppression of cancer cell proliferation is very pronounced and exceeds that of Doxorubicin (Positive Control).

The obtained results suggest that the proposed drugs help to suppress the proliferation of chemoresistant lung adenocarcinoma cells.

Example No. 3.

A drug diluted from 10 ^-3 to 10 ^-7 mmol / l was introduced into the culture medium on matrices with the experimental ACNH group (human chemoresistant renal adenocarcinoma). Control group — Doxorubicin, which is presented on the graph as PC, is introduced into test tubes with the same pool of cancer cells.

After thermostating for 3 days at a temperature of 37 ° C, an analysis of proliferative activity was carried out.

Consideration of the results in examples 3 and 4 showed:

In test tubes of the test group with the drug introduced, the suppression of cancer cell proliferation is very pronounced and exceeds that of Doxorubicin.

The obtained results suggest that the proposed drugs help to suppress the proliferation of chemoresistant lung adenocarcinoma cells.

Example No. 4.

The filtrate from sarcoma 45 (5 ml) was placed in a quartz cuvette, spectrophotometry was performed.

"Then a solution of 3,3'-Diethylthiatricarbocyanine iodide was introduced into this filtrate for 2 hours, then repeated spectrophotometry was performed.

Results: In the images without the drug, the absorption spectrum is in the region of 277 nm, and the emission in the region of 419 nm. In the photographs after drug administration, a shift in the absorption spectrum is noted: the far part of the UV radiation up to 280 nm and luminescence up to 420 nm, respectively.

It is known from the literature that a shift of 2–3 nm in the UV part of the spectrum indicates large changes in the structure of organic molecules. Therefore, the drug restores structural disorders of proteins that occur during malignancy.

The data obtained indicate, firstly, that protein structures are violated in the serum of cancer patients, because normally, the absorption and emission band of tryptophan-based protein structures is 280 and 420 nm, respectively. Secondly, the regulatory effect of the drug on structural changes in the proteins of cancer cells is clearly shown.

Treatment examples

Example No. 5.

Patient P., 43 years old. Four years ago, the left mammary gland was removed and prophylactic chemotherapy for duct cancer was performed. When examining on CT in the projection of the right lobe of the liver, the tumor formation is 3.4 × 4.4 × 3.3 cm, as well as two tumor formations with a diameter of 3.1 to 2.8 cm in the right lung. On scintigraphy, a metastatic lesion of the lumbar vertebrae and wing of the right ilium. Severe condition, cachexia, shortness of breath, cyanosis, adynamia. When calculating the size of lymphocytes in a blood smear, there was a sharp decrease in small lymphocytes, an increase in large lymphocytes and a positive reaction of blood lymphocytes to the breast cancer antigen (with a blocking effect of serum). Which also spoke about the severity of the disease. Treatment has been prescribed, including the use of an antitumor drug. The drug 3,3'-Diethylthiatricarbocyanine iodide was administered by mouth in the form of a drink of 30 drops of a 1% solution three times a day and in the form of microclysters of 20 drops of a 1% solution and 200 mg intravenously per 500 ml of physiological saline. After 4 weeks of treatment, shortness of breath and pain decreased. Blood tests during treatment returned to normal within 3 months. The ratio of large and small lymphocytes returned to normal. Next, a second course of the drug was carried out, which was injected into the rectum in the form of 1% suppositories and inhaled 30 drops of a 1% solution weekly for 6 months. Once a month, “Zamet” (bisphosphonates) was administered. During therapy, bone metastases were calcified, disappeared in the liver and lungs. Weight restored. There are no complaints.

Example No. 6.

Patient S., 64 years old. Diagnosis: Small cell adenocarcinoma of the right lung. MTS to the liver. Two years ago, a resection of the right lung was performed. A year later, chest pain, shortness of breath and hemoptysis appeared. On CT in the right lung, a tumor formation of 2 × 4 × 3 cm is determined. Small multiple metastases are visible in the region of the right lobe of the liver. In the pleural cavity on the right, free fluid is up to 800 milliliters. The state of moderate severity, pallor of the skin, cachexia. The treatment with the drug was started according to the scheme of 20 drops of 1% solution. The drug 3,3'-Diethylthiatricarbocyanine iodide per half a glass of water through the mouth and in the form of microclysters. Inhalation 2 times a day 20 drops of 1% solution.

The course lasted 6 months. During treatment, the tumor decreased in size to 1.1 × 1.9 × 1.0 cm. In the second week from the start of treatment. shortness of breath disappeared, stool returned to normal, and pain disappeared. Blood tests during treatment returned to normal within 2 months. A full course of treatment with the drug for 12 months. During therapy, a tumor in the lung area, exudate in the pleural cavity and small metastases in the liver disappeared. Weight restored.

Example No. 7

Patient U., 64 years old. Diagnosis: Brain astrocytoma on the left. Relapse. Four years ago, a tumor was extirpated due to brain astrocytoma. Three years later, headaches, nausea, and vomiting appeared. On an MRI in the projection of the p / operative scar in the substance of the brain, a tumor with uneven edges of 4.8 × 3.4 cm is determined. The condition is moderate, pallor of the skin, ataxia. The patient was prescribed the drug 3,3'-Diethylthiatricarbocyanine iodide 500 mg per 500 ml of saline in sterile form, intravenously, drip. Procedure for 40 minutes. Subsequent procedures were carried out in exactly the same sequence 3 times a week. The course lasted 4 months. During treatment, the tumor decreased in size to 0.6x0.5 cm. After two infusions of the drug, nausea and pain decreased. Over the next 12 months, a single injection of the drug was carried out every two weeks. On a CT scan after 12 months of treatment at the tumor site, a formation with signs of calcification of 0.2 × 0.3 cm.

Example No. 8

Patient A., 54 years old. Diagnosis: Squamous cell carcinoma of the right lung. MTS to the liver, spine and ribs. Chemotherapy was performed a fortnight before treatment. Complaints of severe pain in the right hypochondrium, shortness of breath. The state of moderate severity, low nutrition, yellowness of the skin. On CT, a tumor of the right lung is determined, and an ultrasound scan of a tumor in the left lobe of the liver with irregular edges of 3 × 5 cm. The patient underwent umbilical vein surgery. For two weeks, twice a day, a sterile preparation of 3,3'-Diethylthiatricarbocyanine iodide, 2 g, dissolved in 100 ml of physiological saline was injected into the catheter. Subsequent procedures were carried out in exactly the same sequence 2 times a week. Only the drug was administered intravenously. For lung treatment, 30 drops of 1% solution of 3,3'-Diethylthiatricarbocyanine iodide are prescribed. The course lasted 3 months. During treatment, the tumor in the region decreased in size to 0.5 × 0.7 cm. After 3 months, the connective tissue scar 0.3 × 0.4 cm remained in the liver at the site of the tumor. In the lungs on CT, the tumor became 80% smaller. There is no shortness of breath and pain. In the course of treatment with the help of the drug, positive dynamics in blood tests were noted.

General blood test results

Main characteristics 08/12/06 10/19/06 12/01/06 01/02/07 Red blood cells 2,52 4.34 4.73 4.48 Hemoglobin 64 79 107 121 Platelets 214 262 386 415

White blood cells 11,2 6.5 5.7 6.5 Basophils 0-1% one - - one Eosinophils 0-5 one 2 2 0 Pal. nuclear 1-6% one one - - Segm. nuclear 45-70 24 45 61 65 Lymphocytes 18-40% eleven 16 23 39 Monocytes 2-9% 13 four 3 6 ESR 1-15 mmh thirty fifteen 5 four

Results of biochemical blood tests

Main characteristics Sod. fine 09/10/06 11/12/06 12/04/06 01/02/07 Total protein 65.0-85.0 42.14 59.5 74 76.34 Creatinine hl 91.0 73 77 57 Urea 44-110 7.9 6.8 3.4 3,7 Cholesterol 1.66-8.3 6.25 5.67 5.73 7.54 Common bilirubin 2.90-6.54 11,4 24.5 8.6 8.1 Bilirubin 8.5-20.5 3.0 22.3 3.3 2.0 straight up to 25% 8.0 11.9 5.1 6.0 Bilirubin up to 25% 82 96 84 90 indirect up to 100 Eat 107.2 102 89 78.0 Amylase 95-110.0 114.0 140 102.8 110.0 Chlorine 135.0- 4.20 4.3 4.0 4.2 Sodium 147.0 1.8 1,0 1.8 1,0 Potassium 3,5-6,0 2.72 2,32 2.28 2.15 Calcium ionization. 0.98-1.30 19,4 13,4 18.0 17.7 Total calcium 2.1-2.55 314.3 395.8 138.0 54,4 Iron syv. 8.8-27.0 190.4 214.7 54,4 43.7 ACT 5-40 Eat 551.5 431.9 103.1 100,4 ALT 5-40 Eat 665.8 429 254.2 240 Phosphatase slit. up to 104 LDH Ate 225-450 Ate

No complaints at this time.

Example No. 10.

Patient L., 28 years old. Diagnosis: non-Hodgkin's lymphoma. Cachexia. A full course of high-dose chemotherapy was conducted 1.5 years ago. Six months ago, tumor-like formations appeared on the neck and under the jaw. An X-ray revealed an expansion of the mediastinum. At the time of treatment, complaints of shortness of breath, weakness, sweating. The state of moderate severity, low nutrition, pale skin. In the submandibular region on the left is a tumor formation of 4 × 3 cm. On the neck on both sides, tumor formation is 3 × 3 × 4 cm. Treatment with 3,3'-Diethylthiatricarbocyanine iodide according to the scheme. 50 drops of a 1% solution of 3,3'-Diethylthiatricarbocyanine iodide, dissolved in 150 ml of water, was taken by mouth three times a day. The course lasted 4 months. After 12 days from the start of treatment, the patient's submandibular lymph nodes completely disappeared. Within a month, tumors in the neck area decreased in size to 0.5 × 0.5 cm. After 4 months, no lymph nodes were detected. Blood and urine tests are normal. Weight restored. There are no complaints.

Example No. 11.

Patient T., 65 years old. Diagnosis: Adenocarcinoma of the colon. MTS in the liver and lungs. Ascites. 4 years ago, a large bowel resection was performed with end-to-end anastomosis. He completed a full course of chemotherapy. 3 years after the operation, pains appeared in the lower abdomen, tenesmus. At the time of treatment, she complains of severe weakness, constant abdominal pain, cough, shortness of breath, ascites, and stool retention. The condition is serious, of poor nutrition, the skin is pale with a cyanotic tinge, the abdomen with signs of ascites. In blood tests, there is a decrease in the number of red blood cells, hemoglobin, white blood cells, albumin, an increase in ALT and ACT. Computed tomography in the right lobe of the liver determines the formation of an irregular shape of 3 × 4 cm with uneven edges. In the area of the anastomosis, a volumetric formation of 5 × 5.6 cm and up to 2 liters of free fluid in the abdominal cavity is determined. The patient was prescribed the drug 3,3'-Diethylthiatricarbocyanine iodide in the form of intravenous infusions, microclysters and drinking. The infusion solution is 200 mg of sterilized 3,3'-Diethylthiatricarbocyanine iodide dissolved in 500 ml of physiological saline. In addition, to enhance the effect, the preparation of 3,3'-Diethylthiatricarbocyanine iodide 1% solution of 200 ml was administered intraperitoneally every time an ascites fluid was evacuated. Infusions were carried out weekly for 3 months. Inhalation of 30 drops of a 1% solution daily for 2 months. Enema is a mixture of 20 g of 3,3'-Diethylthiatricarbocyanine iodide per 1500 ml of boiled water. Enema was taken three times a week for 2 months. After 10 days from the start of treatment, the patient completely disappeared pain and appetite. In the third week of treatment, shortness of breath decreased. During treatment, the tumor in the anastomotic area decreased in size to 0.2 × 0.3 cm. After 3 months, a month-long break was made, and then the treatment continued for 2 months. During treatment, metastases in the liver, lung and tumor in the anastomotic region are not determined. Marked gradual improvement in blood counts is noted, which is directly related to drug treatment.

Blood test results

Main characteristics 04/07/06 06/24/06 09.09.06 11/09/07 Red blood cells 3.12 3.34 4.44 4.87 Hemoglobin 71 94 115 128 Platelets 120 210 326 440 White blood cells 9.2 12.0 5.2 5.3 Basophils 0-1% one - - one Eosinophils 0-5 one 2 2 one Pal. nuclear 1-6% 0 one - 2 Segm. nuclear 45-70 2 6 6 5 Lymphocytes 18-40% 35 49 58 69 Monocytes 2-9% 13 four 7 9 ESR 1-15 mmh 36 12 10 5 Results of biochemical blood tests Main characteristics Sod. fine 04/07/06 06/24/06 09.09.06 11/09/07 Total protein 65-80 g / l 51.23 62.26 65 82.53 Creatinine 85.0 g / l 118.0 89 74 69 Urea 44-110 8.2 7.4 3,1 2.9. Cholesterol 1.66-8.3 6.21 5.62 5.75 7.03 Common bilirubin 2.90-6.54 11.0 24.2 8.4 8.0 Bilirubin 8.5-20.5 3.0 22.3 3.3 2.0 Straight up to 25% 8.0 11.9 5.1 6.0 Bilirubin up to 25% 82 96 84 90 Indirect up to 100 ate 107,2 102 89 78.0 Amylase 95-110.0 114.0 140 102.8 110.0 Chlorine 135.0- 114.20 115.3 114.31 134.2 Sodium 147.0 3.8 4.9 4.8 4.9 Potassium 3,5-6,0 2.72 2,32 2.28 2.15 Calcium ionization. 0.98-1.30 19,4 13,4 18.0 17.7 Total calcium 2.1-2.55 314.3 395.8 138.0 64,4 Iron syv. well 8.8-27.0 190.4 104.7 54.8 42.9 ACT 5-40 ate 265.7 125.8 45.7 29.5 ALT 5-40 ate Phosphatase slit. well up to 104 465.8 326 69.2 79 LDH Ate 623 332 242 228 225-450 Ate

Weight restored. There are no complaints.

Example No. 12.

Patient E., 53 years old. When handling complaints of pain during urination and retention and redness of urine. On examination: TRUS in the urinary bladder near the right ureter, a tumor with fuzzy contours 2.0 × 4.2 cm. Puncture biopsy - squamous cell carcinoma of the bladder. Diagnosis: Squamous cell carcinoma of the bladder. He refused surgery and chemotherapy. The drug was treated with 3,3'-Diethylthiatricarbocyanine iodide.

For 60 days, the patient took the drug - the drug 3,3'-Diethylthiatricarbocyanine iodide 300 mg was diluted in sterile saline and was administered through a catheter twice a week. During the meal, the drug 3,3'-Diethylthiatricarbocyanine iodide was taken in capsules of 200 mg. At night, a candle was administered with 2% of the drug. During this period, the pain during urination decreased, the color of the urine returned to normal, the volume of the tumor decreased by 40% by ultrasound, the tumor acquired a clear outline, dimensions 1.3 × 1.4 cm. Then the therapy was continued by taking 300 mg × for two weeks. 2 times a day with meals, respectively, 300 mg of 3,3'-Diethylthiatricarbocyanine iodide, respectively, and prescribed therapeutic enemas daily at bedtime, 2.0 g of 3,3'-Diethylthiatricarbocyanine iodide in 30 ml of boiled water.

Upon subsequent examination, according to the patient's words, the final disappearance of the symptoms of the disease (pain during urination, urinary retention, etc.) was noted.

Example No. 13.

Patient M., 46 years old. Diagnosis: Squamous cell carcinoma of the right cheek. In the region of the right cheek, a mushroom-shaped neoplasm of dark brown color 4 × 6 × 5 cm with perifocal edema and ulceration in the center. Histological diagnosis: Squamous cell carcinoma of the skin. 5% ointment based on cocoa butter and 3,3'-Diethylthiatricarbocyanine iodide was treated. Within 1 month, the size of the tumor decreased by 90%. After 3 months, hyperpigmentation and a small scar are determined at the site of the tumor. No complaints. No relapse for 2 years.

As a result of the invention, an agent having high antitumor activity and therapeutic effect in relation to various oncological diseases was created.

At the same time, a widely available and inexpensive substance that is non-toxic and does not cause side effects when used in pharmaceutically acceptable doses is used as an agent for the treatment of oncological diseases. At the same time, the terms are shortened and the treatment is more effective.

Claims (9)

1. The use of 3,3'-diethylthiatricarbocyanine iodide C25H25N2S2.I, (3,3-diethilthiatricarbocyanine iodide) having the structural formula:

as a means for the treatment of cancer with a single dose of from 0.1 mg to 5 g per reception up to 3 times a day. 2. The use according to claim 1, characterized in that the 3,3'-diethylthiatricarbocyanine iodide is used in a dilution of 10 ^-7 to 10 ^-5 mmol / l in water or in physiological saline. 3. The use according to claim 1, characterized in that 3,3'-diethylthiatricarbocyanine iodide in the form of an aqueous solution is taken before or after a meal. 4. The use according to any one of claims 1 to 3, characterized in that the aqueous solution of 3,3'-diethylthiatricarbocyanine iodide is administered rectally. 5. The use according to any one of claims 1 and 2, characterized in that a 1% solution of 3,3'-diethylthiatricarbocyanine iodide is administered intravenously and intraperitoneally. 6. The use according to any one of claims 1 and 2, characterized in that a 1% solution of 3,3'-diethylthiatricarbocyanine iodide is administered by inhalation. 7. The use according to any one of claims 1 and 2, characterized in that 1-5% ointment of 3,3'-diethylthiatricarbocyanine iodide is used. 8. The use according to any one of claims 1 and 2, characterized in that the 3,3'-diethylthiatricarbocyanine iodide is administered rectally in the form of 1-2% suppositories. 9. The use according to any one of claims 1 and 2, characterized in that the solution of 3,3'-diethylthiatricarbocyanine iodide is administered intramuscularly with a single dosage of from 100 to 200 mg.